0001562180-18-003545.txt : 20180809 0001562180-18-003545.hdr.sgml : 20180809 20180809192239 ACCESSION NUMBER: 0001562180-18-003545 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180807 FILED AS OF DATE: 20180809 DATE AS OF CHANGE: 20180809 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kummeth Charles R. CENTRAL INDEX KEY: 0001534980 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 181006767 MAIL ADDRESS: STREET 1: 425 MARTINGALE ROAD STREET 2: SUITE 1000 CITY: SCHAUMBURG STATE: IL ZIP: 60173-2213 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2018-08-07 false 0000842023 BIO-TECHNE Corp TECH 0001534980 Kummeth Charles R. 425 MARTINGALE ROAD SUITE 2050 SCHAUMBURG IL 60173-2213 true true false false Chief Executive Officer Common Stock 2018-08-07 4 M false 13816.00 0.00 A 90288.00 D Common Stock 2018-08-07 4 F false 6301.00 180.14 D 83987.00 D Common Stock 2018-08-07 4 F false 1752.00 180.14 D 82235.00 D Common Stock 2018-08-08 4 A false 11279.00 0.00 A 93514.00 D Restricted Stock Units 2018-08-07 4 M false 13816.00 0.00 D Common Stock 13816.00 3467.00 D Restricted Stock Units 2018-08-07 4 D false 3467.00 0.00 D Common Stock 3467.00 0.00 D Stock Options (Right to buy) 108.49 2018-08-07 4 D false 23929.00 0.00 D 2022-08-07 Common Stock 23929.00 95346.00 D Restricted Stock Units 2018-08-08 4 A false 16918.00 0.00 A Common Stock 16918.00 16918.00 D Stock Options (Right to buy) 177.32 2018-08-08 4 A false 60222.00 0.00 A 2025-08-08 Common Stock 60222.00 60222.00 D Stock Options (Right to buy) 177.32 2018-08-08 4 A false 90334.00 0.00 A 2025-08-08 Common Stock 90334.00 90334.00 D Restricted Stock Units Common Stock 24979.00 24979.00 D Restricted Stock Units Common Stock 21291.00 21291.00 D Stock Option (Right to Buy) 108.49 2022-08-07 Common Stock 79517.00 79517.00 D Stock Option (Right to Buy) 106.59 2023-08-18 Common Stock 102779.00 102779.00 D Stock Option (Right to Buy) 106.59 2023-08-18 Common Stock 154169.00 154169.00 D Stock Option (Right to Buy) 86.25 2021-04-01 Common Stock 46316.00 46316.00 D Stock Option (Right to Buy) 67.46 2020-04-01 Common Stock 65000.00 65000.00 D Stock Option (Right to Buy) 67.46 2020-04-01 Common Stock 50000.00 50000.00 D Stock Options (Right to buy) 125.05 2024-08-09 Common Stock 117342.00 117342.00 D Stock Options (Right to buy) 125.05 2024-08-09 Common Stock 78228.00 78228.00 D Stock Options (Right to buy) 94.35 2021-08-12 Common Stock 66849.00 66849.00 D Restrictions lapse as to 3,760 shares on 8/8/19 and 8/8/20 and as to 3,759 shares on 8/8/21 Includes (i) 11,102 shares of restricted stock for which the risks of forfeiture will lapse with respect to 5,551 shares on each of August 18, 2018 and August 18, 2019; (ii) 14,194 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on each of August 9, 2018 and August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2010 and as to 3,759 shares on August 8, 2021. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. On 8/7/2018, the Board of Directors authorized discretionary vesting for 13,816 performance RSUs. The remainder of the performance RSUs were forfeited. On 8/7/2018, the Board of Directors authorized discretionary vesting for 95,346 performance options. The remainder of the performance options were forfeited. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Vests 15,056 shares each on 8/8/2019, 8/8/2020, and 15,055 shares each on 8/8/2021, 8/8/2022. Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 19,879 shares vest on each of August 7, 2016, August 7, 2017 and August 7, 2018 and 19,880 shares vest on August 7, 2019. Vests 25,695 shares on each of 8/18/17, 8/18/18, and 8/18/19 and 25,694 shares on 8/18/20. Fully exercisable Vests 19,557 each on 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021 /s/ Brenda S. Furlow, attorney in fact for Charles R. Kummeth pursuant to Power of Attorney previously filed 2018-08-09 EX-24 2 kummethpoa2017.txt KUMMETHPOA2017 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Brenda S. Furlow, James Hippel, Anna Weispfenning, Melodie R. Rose, Andrew Nick, Sarah Tucher or either of them acting alone, the undersigned's true and lawful attorneys- in-fact and agent with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to sign any or all Forms 3, Forms 4 and Forms 5 relating to beneficial ownership of securities of Bio-Techne Corporation (the "Issuer"), to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and to deliver a copy of the same to the Issuer, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all said attorneys-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in effect until such time as the undersigned is no longer subject to the provisions of Section 16 of the Securities Exchange Act of 1934 with respect to securities of the Issuer. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of October, 2017. /s/ Charles R. Kummeth